Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00079755 · ClinicalTrials.gov registry record · Phase 2
Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell Lymphoma
A Phase 2 study, sponsored by Seagen.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT00079755 is a Phase 2 study that has completed, run by Seagen. The registered enrollment target is 80 participants.
The verdict
NCT00079755, a Phase 2 study, has completed, sponsored by Seagen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
To investigate safety and antitumor activity of SGN-30 in patients with Hodgkin's Disease and anaplastic large cell lymphoma (ALCL). As of March 22, 2005, interim analysis of the Hodgkin's Disease (HD) arm has been completed per the statistical plan in the protocol. SG030-0003 is now closed to further recruitment of HD patients.
Interventions
- DRUG SGN-30 (anti-CD30 mAb)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2004-02 |
| Est. Completion | 2006-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00079755
The ClinicalTrials.gov registry entry for NCT00079755 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, which has 84 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SGN-30 (anti-CD30 mAb) is the first listed.
NCT00079755 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00079755 about?
NCT00079755 is a clinical study titled "Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell Lymphoma". To investigate safety and antitumor activity of SGN-30 in patients with Hodgkin's Disease and anaplastic large cell lymphoma (ALCL). As of March 22, 2005, interim analysis of the Hodgkin's Disease (HD) arm has been completed per the statistical plan in the protocol. SG030-0003 is now closed to furt...
What is the current status of trial NCT00079755?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2004-02. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00079755?
The interventions under investigation include: SGN-30 (anti-CD30 mAb) (DRUG).
Who is sponsoring clinical trial NCT00079755?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.